Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

COMT inhibitors with terminal olefinic bond and hydrazide structures as well as preparation method and use of COMT inhibitors

A technology of hydrazine hydrate and cyclopentadiene, which can be used in the fields of nervous system diseases, organic chemistry, drug combination, etc., and can solve problems such as limited applications

Inactive Publication Date: 2018-04-20
FOSHAN SAIWEISI MEDICINE SCI & TECH
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Although clozapine, Zyprexa, Vistron, and other antipsychotics have been used to treat both positive and negative (controversial) symptoms of schizophrenia and bipolar disorder, these drugs have not been free from side effects such as Cytopenia, sedation, weight gain, hyperlipidemia and hyperglycemia, all of which limit their use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • COMT inhibitors with terminal olefinic bond and hydrazide structures as well as preparation method and use of COMT inhibitors
  • COMT inhibitors with terminal olefinic bond and hydrazide structures as well as preparation method and use of COMT inhibitors
  • COMT inhibitors with terminal olefinic bond and hydrazide structures as well as preparation method and use of COMT inhibitors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] The synthesis of embodiment 1 compound I-1

[0021]

[0022] Step 1. Synthesis of Compound VI-1

[0023] Compound II (1.32g, 20mmol) was dissolved in 20mL DMSO, stirred at room temperature, KOH solid (2.24g, 40mmol) was added, and stirred at room temperature for 1 hour. Further MeI (III-1, 2.84 g, 20 mmol) was added, and stirring was continued overnight at room temperature. Then tert-butyl bromoacetate V (3.90 g, 20 mmol) was added, and the stirring was continued for 12 hours. TLC detection found that the reaction was complete. The reaction mixture was carefully poured into 200mL ice water, stirred, and washed with 50mL×3CH 2 Cl 2 After extraction, the extract phases were combined, washed with 100 mL of 5% brine, and dried over anhydrous sodium sulfate. The desiccant was removed by suction filtration, the filtrate was evaporated to dryness on a rotary evaporator, and the residue was purified by silica gel column chromatography to obtain compound VI-I, 2.99 g (co...

Embodiment 2

[0028] The synthesis of embodiment 2 compound 1-2

[0029]

[0030] Step 1. Synthesis of compound VI-2

[0031] Compound II (1.32g, 20mmol) was dissolved in 20mL DMSO, stirred at room temperature, KOH solid (2.24g, 40mmol) was added, and stirred at room temperature for 1 hour. III-2 (2.42 g, 20 mmol) was added again, and stirring was continued overnight at room temperature. Then add V 20mmol again, continue stirring for 12 hours, TLC detection finds that the reaction is complete. The reaction mixture was carefully poured into 200mL ice water, stirred, and washed with 50mL×3CH 2 Cl 2After extraction, the extract phases were combined, washed with 100 mL of 5% brine, and dried over anhydrous sodium sulfate. The desiccant was removed by suction filtration, the filtrate was evaporated to dryness on a rotary evaporator, and the residue was purified by silica gel column chromatography to obtain compound VI-2. ESI-MS, m / z=235 ([M+H] + ).

[0032] Step 2. Synthesis of Compo...

Embodiment 3

[0036] Example 3 Compound Inhibition COMT Analysis in Vitro

[0037] The COMT inhibitory activity of the compounds of the present invention was determined using the experimental method described below. The fluorescence assay is based on the methylation of a substrate (6,7-dihydroxycoumarin) by COMT to generate a highly fluorescent product (7-hydroxy-6-methoxycoumarin). The reaction requires the presence of magnesium ions and a methyl donor, in this case S-adenosylmethionine (SAM)]. A 10-point 3-fold dilution series was prepared using 10 mM compound stocks in DMSO and 1 μL of the appropriate dilution was placed in assay wells (black 96-well round bottom polystyrene plates from Costar; cat. no. 3792). Dilute the recombinant enzyme in assay buffer (100mM Na 2 HPO 4 pH 7.4, 1 mM DTT, 0.005% Tween-20) and 35 μL was added to assay wells containing 1 μL of compound. Pre-incubation of COMT enzyme and compound was performed for 2 hours at room temperature. Use 5 μL containing 40...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of COMT inhibitors, and in particular relates to COMT inhibitors with terminal olefinic bond and hydrazide structures as well as a preparation method of the COMT inhibitors and application of the COMT inhibitors to preparation of medicines for treating schizophrenia, and the like. The general formula (I) of the COMT inhibitors is described in the description.

Description

technical field [0001] The present invention relates to the field of COMT inhibitors. Specifically, the present invention relates to a COMT inhibitor containing a terminal ethylenic bond and a hydrazide structure, which has a therapeutic effect on inhibiting COMT, its preparation method and its application in the treatment of schizophrenia. Background technique [0002] Symptoms of schizophrenia are generally divided into three categories: positive, negative and cognitive. Positive symptoms include hallucinations, delusions, and disorganized behavior, while negative symptoms are characterized by a lack of pleasure and / or interest in life. Cognitive deficits include difficulty organizing thoughts and prioritizing tasks. Patients with bipolar disorder typically display cyclical mood swings (with or without psychotic features) from severe depression to severe mania. Schizophrenia and bipolar disorder are among the most severe types of mental disorders causing overlapping cog...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D251/50A61P25/18
CPCC07D251/50
Inventor 蔡子洋
Owner FOSHAN SAIWEISI MEDICINE SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com